| --- | --- | |-------|-------| | | | | | | 2 Lumos Pharma Q2 2020 Conference Call • Lisa Miller, Director of Investor Relations • Rick Hawkins, CEO Agenda • John McKew, PhD, COO & CSO • Eugene Kennedy, MD, CMO • Carl Langren, CFO Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Lisa Miller - Director, IR Rick Hawkins - CEO, President, and Chairman John McKew - COO and Chief Scientific Officer Gene Kennedy - Chief Medical Officer Carl Langren - CFO Conference Call Participants Ed White - H.C. Wainwright Eun Yang - Jefferies Elemer Piros - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Lumos Pharma's Second Quarter 2020 Earnings C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2020. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUMOS PHARMA, INC. (Exact name of Registrant as specified in Its Charter) (State or other jurisdiction of incorpo ...

ll I mos PHARMA Corporate Presentation May 2020 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," ...

Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2020 Earnings Conference Call May 28, 2020 4:30 PM ET Company Participants Lisa Miller – Director-Investor Relations Rick Hawkins – President and Chief Executive Officer John McKew – Chief Operating Officer and Chief Scientific Officer Gene Kennedy – Chief Medical Officer Carl Langren – Chief Financial Officer Conference Call Participants Eun Yang – Jefferies Ted Tenthoff – Piper Sandler Yasmeen Rahimi – Roth Capital Partner Operator Good afternoon. Ladies and gentlemen, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2019. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or other jurisdiction of incorporation or org ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2019. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or other jurisdict ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2019. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or other jurisdiction o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Delaware 42-1491350 Washington, D.C. 20549 FORM 10-Q ý Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2019. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2018. o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or other jurisdiction of incorporation or org ...